我們想到一塊兒去了。現在政府也不知道咋辦，看看NCI怎麽說。。。

我們想到一塊兒去了。現在政府也不知道咋辦，看看NCI怎麽說。。。mammograms政府不知道。病人太少，長期研究要花太多人力物力。關鍵超聲， MRI單獨做screen有問題。

放療問題應該更大一些，請看下麵最後一段。

http://www.cancer.gov/about-cancer/causes-prevention/genetics/ataxia-fact-sheet

Is it dangerous for ATM mutation carriers to have diagnostic x-rays, given their possible increased sensitivity to radiation compared to the general public?

At this point, the evidence overall does not show a documented risk to ATM mutation carriers. However, diagnostic x-rays should be limited because of the theoretical risk that the x-ray may cause a chromosomal break, which could result in the development of a malignancy. In general, x-rays should only be done if the result will influence therapy and there is no other way to obtain the information that the x-ray will provide.

 

Suppose I learn I am an ATM mutation carrier. Will mammography increase my chances of getting breast cancer?

There is not yet definitive evidence that ATM mutation carriers of any age have increased sensitivity to x-rays from mammograms or other diagnostic tests.

Clinical breast examination and breast ultrasound are approaches to screening that avoid radiation exposure. When exposure to radiation is required, doctors who treat ATM mutation carriers should use the most modern equipment and technology available, in order to minimize radiation exposure.

 

What about environmental sources of radiation, such as cellular phones? Should ATM mutation carriers avoid these exposures?

In NCI studies to date, no link has been found between non-ionizing radiation—such as that from cellular phones and power lines—and cancer.

 

What studies does NCI have under way to answer these questions more definitively?

NCI is sponsoring a wide variety of research on A-T, DNA mutations and repair, and the interaction between ATM and mutations in BRCA1 and BRCA2 (breast cancer susceptibility genes). Clinical scientists at NCI have over 30 years of experience with A-T, and are continuing research to develop better diagnostic tests, immune dysfunction analyses, and treatments.

In addition, NCI is supporting three large, multi-national studies investigating A-T. One population-based study, a collaboration of investigators from the United States, Canada, Costa Rica, Germany, Israel, Italy, Poland, and Turkey, is examining the risk of cancer in A-T patients and their relatives. NCI is conducting another analysis of cancer risk in A-T families in collaboration with registries in Norway, Sweden, Denmark, and Finland. Another large, multi-site study, taking place in the United States and Denmark, is investigating whether women who are ATM mutation carriers who have received radiation therapy as part of breast cancer treatment are at high risk of developing a second breast cancer in the other breast (second primary contralateral breast cancer).

所有跟帖： 

• 謝謝你提供的信息。這位作者的妹妹應該去做這個基因檢測和MRI（自費也值得），而不是一味地依賴增加mammogram的次數。 -Lily168- ♀ (131 bytes) () 11/15/2015 postreply 10:39:19

• 同意！一年兩次鉬靶對正常人也太多了。政府指南才2年一次。希望她們能找到願意隻讀MRI的放射科醫師。。。 -誌在千裏- ♀ (207 bytes) () 11/15/2015 postreply 15:24:37